Addex Therapeutics Ltd. (ADXN)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.90
- As of
Kresmion compiles this page from ADXN's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Addex Therapeutics Ltd. (ADXN): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-10-29.
See the full ADXN dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for ADXN on one page. Preview it with sample data, then open it live with a free account.
Preview the ADXN dossierActive events for ADXN
No recent events on ADXN in the last 180 days.
FREE, NO ACCOUNT
Every event on ADXN, as it fires
New filings, 13F moves and cross asset events on ADXN land in the record first.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
No non-option holdings from tracked managers in this reporting quarter.
Recent SEC filings, ADXN
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
Going concern statement
ADXN's 20-F filed May 15, 2026 states:
As stated in Note 4, these events or conditions, along with other matters as set forth in Note 4, raise substantial doubt about the Group's ability to continue as a going concern.
Read the 20-F on SEC EDGAR Every company with a going concern statement
More data on ADXN
ADXN against its peers
ADXN's net margin of 1746.0% ranks in the 92nd percentile of 5 Biotechnology sub-industry peers, fiscal period ending 2024-12-31.
| Metric | ADXN | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 404102 CHF | n/a | n/a | 0 |
| Revenue YoY | -74.9% | n/a | n/a | 3 |
| Operating margin | -681.8% | n/a | n/a | 4 |
| Net margin | 1746.0% | -989.3% | 92 | 5 |
| Return on equity | 72.9% | n/a | n/a | 4 |
Peers (5): CDIO, NIKI, CANF, EVGN, CSCIF. Left out: OSRH (period gap), PULM (period gap), SNGX (period gap), CELZ (period gap), ADAPY (no annual filing), CNSY (period gap), JAGX (period gap), PCSA (period gap), IMNN (period gap), BGMS (period gap), LGVN (period gap), ACXP (period gap), AZTR (period gap), OTLC (period gap), ALZN (period gap), RVPH (period gap), XBIO (period gap), SKYE (period gap), TCRT (period gap), APTOF.D (period gap). Fiscal period ending 2024-12-31. Every figure is one full fiscal year read from one annual filing (ADXN: 20-F), reported in CHF. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in ADXN on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on ADXN in the last 180 days.
Upstream: SEC EDGAR filings for ADXN
Kresmion, "Addex Therapeutics Ltd. (ADXN) institutional holdings and SEC filings", data as of 2026-10-29, https://kresmion.com/research/ADXN. Upstream data: SEC EDGAR filings for ADXN.
Link to this data (HTML):
<a href="https://kresmion.com/research/ADXN">Addex Therapeutics Ltd. (ADXN) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow ADXN on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to ADXN for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.